Atrial Fibrillation (AF)MOTIVE-AFNCT07897305
Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
A study testing Mazdutide and Conventional treatment in people with Atrial Fibrillation (AF) and Ablation Treatment, run by Beijing Anzhen Hospital at 1 site in China.
Trial summary
This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfully regained normal heart rhythm after… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Atrial Fibrillation (AF), Ablation Treatment, Obesity & Overweight
- What is being tested?
- Mazdutide and Conventional treatment
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 700 participants
- Where
- 1 siteChina
- Study dates
- 25 Oct 2026to 30 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18-75 years (inclusive);
- BMI ≥ 28 kg/m², with waist circumference ≥ 90 cm for male subjects and ≥ 85 cm for female subjects;
- Patients with non-valvular atrial fibrillation (AF) undergoing their first AF catheter ablation and maintaining sinus rhythm within 24 hours post-ablation;
- Anteroposterior diameter of the left atrium (excluding transverse and superoinferior diameters) measured from the parasternal long-axis view on echocardiography < 55 mm;
- Agree to randomization as specified in this study and be able to complete follow-up assessments as required.
Who cannot join
- ### Surgery-related
- AF caused by reversible etiologies;
- Left ventricular ejection fraction (LVEF) < 30 % on echocardiography;
- Unstable angina, acute myocardial infarction, or percutaneous coronary intervention (PCI) within the preceding 1 month;
- Patients with severe coronary artery stenosis without prior PCI;
- Stroke, transient ischemic attack (TIA), intracerebral hemorrhage, or any embolic event within the preceding 1 month;
Show all 43Show fewer
- Severe congenital heart disease, such as tetralogy of Fallot, corrected transposition of the great arteries, etc.;
- Hypertrophic cardiomyopathy;
- Moderate or greater aortic stenosis, moderate or greater mitral stenosis;
- Severe hepatic dysfunction (Child-Pugh Class 3), renal insufficiency (eGFR < 30 mL/min/1.73 m²), or a history of renal dialysis, kidney transplantation, or nephrectomy;
- Prior cardiac surgery, including coronary artery bypass grafting, mechanical or bioprosthetic valve replacement, etc.;
- Post-implantation of intracardiac devices, such as pacemaker implantation, left atrial appendage closure, patent foramen ovale closure, atrial septal defect transcatheter closure, etc.;
- Contraindications to anticoagulant therapy;
- Presence of an inferior vena cava filter, or contraindications to right- or left-heart catheterization (e.g., left atrial thrombus, etc.).
- ### Medications or treatments received prior to screening
- Self-reported body weight change > 5 % within 90 days before screening;
- Use (past or current) of anti-obesity medications within 90 days before screening, including sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, mazindol, diethylpropion, lorcaserin, phentermine-topiramate combination, naltrexone-bupropion combination, and GLP-1 receptor agonists (liraglutide, benaglutide, semaglutide, tirzepatide, mazdutide), etc.;
- Use of weight-altering medications within 90 days before screening: systemic corticosteroids (intravenous, oral, or intra-articular administration), tricyclic antidepressants, psychotropic or sedative agents (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, lithium salts), etc.;
- Use of weight-modulating Chinese herbal medicines, health supplements, or meal replacements within 90 days before screening.
- ### Medical history or documented evidence of any of the following disorders
- Prior bariatric-metabolic surgery or planned bariatric-metabolic surgery within 1 year;
- Obesity secondary to underlying diseases or medications: e.g., hypercortisolism (Cushing's syndrome), obesity due to pituitary-hypothalamic injury, obesity following dose reduction/discontinuation of anti-obesity drugs, monogenic obesity, etc.;
- Confirmed type 1 diabetes mellitus;
- Prior severe hypoglycaemia or recurrent symptomatic hypoglycaemic episodes (≥ 2 events within 6 months before screening);
- History of retinopathy;
- Abnormal thyroid function (including TSH ≤ 0.1 mIU/L or ≥ 10 mIU/L) within 7 days before screening, or history of thyroid surgery;
- Personal or family history of pancreatitis;
- Personal or family history of medullary thyroid carcinoma;
- Personal or family history of multiple endocrine neoplasia syndrome type 2;
- History of malignant neoplasm or malignant tumour in remission;
- History of moderate-to-severe depression; or history of severe psychiatric disorders including schizophrenia, bipolar disorder, etc.;
- Prior suicidal ideation or suicidal behaviour;
- Limb deformity or amputation precluding accurate measurement of height and body weight;
- Post-procedural 12-lead ECG showing sinus heart rate < 50 beats/min, second- or third-degree atrioventricular block, long-QT syndrome, or QTcF > 450 ms (male), QTcF > 470 ms (female);
- Contraindications or known hypersensitivity to mazdutide.
- ### Exclusion by laboratory values at screening
- Serum calcitonin ≥ 50 ng/L (pg/mL);
- Fasting triglycerides ≥ 5.64 mmol/L (500 mg/dL);
- Serum amylase or lipase > 2.0 × upper limit of normal (ULN).
- ### Other criteria
- Pregnant or lactating women; subjects (male or female) of child-bearing potential who plan pregnancy within 1 year or decline contraception throughout the study period and for 8 weeks after study completion;
- Life expectancy < 1 year due to malignancy, severe organ failure, or other conditions;
- Any other conditions that, in the investigator's judgement, render the subject unsuitable for study participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
Beijing
About this study
Official title: Efficacy of Mazdutide in Reducing Recurrence After Catheter Ablation in Obese Patients With Atrial Fibrillation: A Multicenter, Superiority, Open-label, Randomized Controlled Trial
This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfully regained normal heart rhythm after their first catheter ablation.
The study aims to compare the efficacy and safety of weekly mazdutide injection with conventional routine care in preventing heart rhythm recurrence within 12 months after ablation (excluding a 3-month early recovery blanking period). A total of 24 months will be spent recruiting participants, followed by a 12-month follow-up period.
Read more
Participants are randomly divided into two groups. The intervention group receives escalating-dose mazdutide subcutaneous injections starting within 48 hours after ablation alongside standard health guidance on diet, exercise and lifestyle. The control group only receives the same routine health guidance without mazdutide treatment.
The primary efficacy endpoint is recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).
- Being tested
- Mazdutide, Conventional treatment
- Keywords
- atrial dibrillation, Catheter ablation, Obesity, Mazdutide
- Medical subject headings
- Atrial Fibrillation, Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MazdutideDrug
- Initiation of mazdutide subcutaneous injection within 48 hours after catheter ablation. Starting dose: 2 mg subcutaneously once weekly using a single-dose pen auto-injector. The initial dose is 2 mg once weekly, increased by 2 mg every 4 weeks during dose escalation, with a maximum dose of 6 mg. The target dose is individualized based on the patient's weight-loss effect. Once the patient achieves a 10% reduction in body weight, the dose is maintained for continued treatment.
- Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence.
Conventional treatmentOther
Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Other | 1. Initiation of mazdutide subcutaneous injection within 48 hours after catheter ablation. Starting dose: 2 mg subcutaneously once weekly using a single-dose pen auto-injector. The initial dose is 2 mg once weekly, increased by 2 mg every 4 weeks during dose escalation, with a maximum dose of 6 mg. The target dose is individualized based on the patient's weight-loss effect. Once the patient achieves a 10% reduction in body weight, the dose is maintained for continued treatment.
2. Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. Receives: Drug: Mazdutide |
| Control Group | Other | Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. Receives: Other: Conventional treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs).
Recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).
Measured: From enrollment to the end of treatment at 52 weeks
Composite serious adverse events (SAEs) occurring during the perioperative period and follow-up period.
- follow-up period, including cardiac tamponade/cardiac perforation, acute cerebrovascular events, acute coronary syndrome, pericarditis, acute kidney injury, third-degree atrioventricular block, serious bleeding events, atrial-esophageal fistula, pericardial-esophageal fistula, pulmonary vein stenosis, death, etc.;
- Incidence of mazdutide-related adverse reactions, such as nausea/vomiting/diarrhea/abdominal pain, elevated serum calcitonin, elevated pancreatic enzymes, severe hypoglycemia, arrhythmia or conduction system disorders, severe liver function abnormality, severe renal function abnormality, thyroid C-cell hyperplasia or thyroid carcinoma, cholelithiasis, acute cholecystitis, cholecystectomy, severe hypersensitivity reactions, etc.
Measured: From enrollment to the end of treatment at 52 weeks
Secondary outcomes (9)
Recurrence of atrial arrhythmias at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) at 12 months after a single ablation procedure (after a 3-month blanking period), with or without the use of Class I/III AADs;
Measured: From enrollment to the end of treatment at 52 weeks
Recurrence of AF at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Recurrence of AF recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of Class I/III AADs;
Measured: From enrollment to the end of treatment at 52 weeks
Recurrence of AT or AFL at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Recurrence of atrial flutter or atrial tachycardia recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of Class I/III AADs;
Measured: From enrollment to the end of treatment at 52 weeks
Recurrence of atrial arrhythmias after single or multiple ablations during the 12-month follow-up
Recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) after single or multiple ablations during the 12-month follow-up, with or without the use of Class I/III AADs;
Measured: From enrollment to the end of treatment at 52 weeks"
AF burden
AF burden (% time) measured at the 12-month follow-up;
Measured: From enrollment to the end of treatment at 52 weeks
Body weight
Changes in body weight in kilograms from baseline to the 12-month follow-up;
Measured: From enrollment to the end of treatment at 52 weeks
Apnea-Hypopnea Index
Changes in Apnea-Hypopnea Index (AHI) from baseline to the 12-month follow-up;
Measured: From enrollment to the end of treatment at 52 weeks
Change in Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT) Score From Baseline to 12 Months
The Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire will be used to assess quality of life. The AFEQT total score ranges from 0 to 120, with higher scores indicating better quality of life. Changes from baseline to the 12-month (52-week) follow-up will be reported.
Measured: From enrollment to the end of treatment at 52 weeks
Cardiovascular-related hospitalizations
Incidence of cardiovascular-related hospitalizations during the 12-month follow-up;
Measured: From enrollment to the end of treatment at 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2026
- Study start25 Oct 2026 (estimated)
- Primary completion30 Dec 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- More trials run by Beijing Anzhen HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Anzhen Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07897305
- Sponsor's protocol ID
- Approval No. (2026)-Keluenshen
- Acronym
- MOTIVE-AF
- Status last verified
- Sep 2026
- First submitted
- 30 Sep 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Mazdutide in Reducing Recurrence After Catheter Ablation in Obese Patients With Atrial Fibrillation: A Multicenter, Superiority, Open-label, Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07897305
- Acronym / sponsor ID
- MOTIVE-AF / Approval No. (2026)-Keluenshen
- Keywords
- atrial dibrillation, Catheter ablation, Obesity, Mazdutide
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Beijing Anzhen HospitalUniversity, hospital or other
- Study start
- 25 Oct 2026 (estimated)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 27 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfully regained normal heart rhythm after their first catheter ablation.
The study aims to compare the efficacy and safety of weekly mazdutide injection with conventional routine care in preventing heart rhythm recurrence within 12 months after ablation (excluding a 3-month early recovery blanking period). A total of 24 months will be spent recruiting participants, followed by a 12-month follow-up period.
Participants are randomly divided into two groups. The intervention group receives escalating-dose mazdutide subcutaneous injections starting within 48 hours after ablation alongside standard health guidance on diet, exercise and lifestyle. The control group only receives the same routine health guidance without mazdutide treatment.
The primary efficacy endpoint is recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Other | Drug: Mazdutide1. Initiation of mazdutide subcutaneous injection within 48 hours after catheter ablation. Starting dose: 2 mg subcutaneously once weekly using a single-dose pen auto-injector. The initial dose is 2 mg once weekly, increased by 2 mg every 4 weeks during dose escalation, with a maximum dose of 6 mg. The target dose is individualized based on the patient's weight-loss effect. Once the patient achieves a 10% reduction in body weight, the dose is maintained for continued treatment. 2. Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. |
| Control Group | Other | Other: Conventional treatmentPatients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Aged 18-75 years (inclusive);
- BMI ≥ 28 kg/m², with waist circumference ≥ 90 cm for male subjects and ≥ 85 cm for female subjects;
- Patients with non-valvular atrial fibrillation (AF) undergoing their first AF catheter ablation and maintaining sinus rhythm within 24 hours post-ablation;
- Anteroposterior diameter of the left atrium (excluding transverse and superoinferior diameters) measured from the parasternal long-axis view on echocardiography < 55 mm;
- Agree to randomization as specified in this study and be able to complete follow-up assessments as required.
Key exclusion criteria (43 listed)
- ### Surgery-related
- AF caused by reversible etiologies;
- Left ventricular ejection fraction (LVEF) < 30 % on echocardiography;
- Unstable angina, acute myocardial infarction, or percutaneous coronary intervention (PCI) within the preceding 1 month;
- Patients with severe coronary artery stenosis without prior PCI;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mazdutide1. Initiation of mazdutide subcutaneous injection within 48 hours after catheter ablation. Starting dose: 2 mg subcutaneously once weekly using a single-dose pen auto-injector. The initial dose is 2 mg once weekly, increased by 2 mg every 4 weeks during dose escalation, with a maximum dose of 6 mg. The target dose is individualized based on the patient's weight-loss effect. Once the patient achieves a 10% reduction in body weight, the dose is maintained for continued treatment. 2. Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. | Drug | Intervention Group |
| Conventional treatmentPatients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence. | Other | Control Group |
Primary outcome
Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs).
Time frame: From enrollment to the end of treatment at 52 weeks
Recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for >30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).
Composite serious adverse events (SAEs) occurring during the perioperative period and follow-up period.
Time frame: From enrollment to the end of treatment at 52 weeks
1. follow-up period, including cardiac tamponade/cardiac perforation, acute cerebrovascular events, acute coronary syndrome, pericarditis, acute kidney injury, third-degree atrioventricular block, serious bleeding events, atrial-esophageal fistula, pericardial-esophageal fistula, pulmonary vein stenosis, death, etc.; 2. Incidence of mazdutide-related adverse reactions, such as nausea/vomiting/diarrhea/abdominal pain, elevated serum calcitonin, elevated pancreatic enzymes, severe hypoglycemia, arrhythmia or conduction system disorders, severe liver function abnormality, severe renal function abnormality, thyroid C-cell hyperplasia or thyroid carcinoma, cholelithiasis, acute cholecystitis, cholecystectomy, severe hypersensitivity reactions, etc.
9 secondary outcomes
Recurrence of atrial arrhythmias at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Time frame: From enrollment to the end of treatment at 52 weeks
Recurrence of AF at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Time frame: From enrollment to the end of treatment at 52 weeks
Recurrence of AT or AFL at 12 months after a single ablation procedure with or without the use of any Class I/III antiarrhythmic drugs (AADs).
Time frame: From enrollment to the end of treatment at 52 weeks
Recurrence of atrial arrhythmias after single or multiple ablations during the 12-month follow-up
Time frame: From enrollment to the end of treatment at 52 weeks"
AF burden
Time frame: From enrollment to the end of treatment at 52 weeks
Body weight
Time frame: From enrollment to the end of treatment at 52 weeks
Apnea-Hypopnea Index
Time frame: From enrollment to the end of treatment at 52 weeks
Change in Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT) Score From Baseline to 12 Months
Time frame: From enrollment to the end of treatment at 52 weeks
Cardiovascular-related hospitalizations
Time frame: From enrollment to the end of treatment at 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mazdutide and Conventional treatment in people with Atrial Fibrillation (AF) and Ablation Treatment, run by Beijing Anzhen Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Deyong Long (+8613522959166, dragon2008@vip.sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs). (time frame: From enrollment to the end of treatment at 52 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.